Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies
Fiona McCartney, Vincent Jannin, Stéphanie Chevrier et al. · Journal of Controlled Release · 2019
Cited by 127 works. doi:10.1016/j.jconrel.2019.08.008
Authors
- Fiona McCartney
- Vincent Jannin
- Stéphanie Chevrier
- Hakime Boulghobra
- Delyan R. Hristov
- Nicolas Ritter
- Cédric Miolane
- Yann Chavant
- Frédéric Demarne
- David J. Brayden
References
- Biopharmaceutical benchmarks 2014
- Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity.
- Biopharmaceutical benchmarks 2018
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
- Ionic liquids for oral insulin delivery
- Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells
- Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials
- Intestinal permeation enhancers for oral peptide delivery
- Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial
- Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10)